Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine

The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0–5 d ol...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hum Vaccin Immunother
Glavni autori: Cowley, Daniel, Boniface, Karen, Bogdanovic-Sakran, Nada, Kirkwood, Carl D., Bines, Julie E.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2017
Teme:
Research Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975418/
https://ncbi.nlm.nih.gov/pubmed/28481726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1323591
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items